Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells
- PMID: 18573140
- DOI: 10.1111/j.1432-2277.2008.00712.x
Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells
Abstract
This report describes the case of patient FR, a 31-year-old recipient of a living-related kidney transplant from a donor against whom he was presensitized. Seventeen days prior to transplantation, a central venous infusion of transplant acceptance-inducing cells (TAICs) was administered to the patient. During the 27-month follow up, the patient experienced no acute rejection episodes under an immunosuppressive regime comprising anti-thymocyte globulin (ATG) induction, corticosteroids and tacrolimus. In a similar manner to the kidney transplant recipients treated preoperatively with TAICs in a previous study, patient FR achieved a state of donor-specific hypo-responsiveness. Most remarkably, the deliberate preoperative exposure of a sensitized patient to the sensitizing alloantigen did not heighten his response; on the contrary, after TAIC treatment and transplantation, HLA-specific antibodies were no longer detectable. The case of patient FR provides further evidence of the safety of pre-transplantation treatment with TAICs.
Similar articles
-
A cell-based approach to the minimization of immunosuppression in renal transplantation.Transpl Int. 2008 Aug;21(8):742-54. doi: 10.1111/j.1432-2277.2008.00692.x. Epub 2008 Jul 10. Transpl Int. 2008. PMID: 18573141 Clinical Trial.
-
Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible.Clin Transplant. 2009 Jan-Feb;23(1):140-5. doi: 10.1111/j.1399-0012.2008.00953.x. Clin Transplant. 2009. PMID: 19200227
-
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation.Transpl Int. 2008 Aug;21(8):728-41. doi: 10.1111/j.1432-2277.2008.00680.x. Epub 2008 Jul 10. Transpl Int. 2008. PMID: 18573142 Clinical Trial.
-
Barriers to successful transplantation of the sensitized patient.Expert Rev Clin Immunol. 2010 May;6(3):449-60. doi: 10.1586/eci.10.14. Expert Rev Clin Immunol. 2010. PMID: 20441430 Review.
-
Passenger lymphocyte syndrome with or without immune hemolytic anemia in all Rh-positive recipients of lungs from rhesus alloimmunized donors: three new cases and a review of the literature.Transfus Med Rev. 2009 Apr;23(2):134-45. doi: 10.1016/j.tmrv.2008.12.003. Transfus Med Rev. 2009. PMID: 19304114 Review.
Cited by
-
Regulatory myeloid cells in transplantation.Transplantation. 2014 Feb 27;97(4):367-79. doi: 10.1097/TP.0b013e3182a860de. Transplantation. 2014. PMID: 24092382 Free PMC article. Review.
-
In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.Mol Ther Methods Clin Dev. 2014 Jul 16;1:14026. doi: 10.1038/mtm.2014.26. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015968 Free PMC article.
-
Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs.Transplant Res. 2012 Sep 28;1(1):17. doi: 10.1186/2047-1440-1-17. Transplant Res. 2012. PMID: 23369628 Free PMC article.
-
The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation.J Nephrol. 2017 Jun;30(3):319-336. doi: 10.1007/s40620-017-0384-z. Epub 2017 Mar 21. J Nephrol. 2017. PMID: 28321822 Review.
-
Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies.Hum Immunol. 2018 May;79(5):314-321. doi: 10.1016/j.humimm.2017.10.017. Epub 2017 Oct 31. Hum Immunol. 2018. PMID: 29100944 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials